Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 6/20 | 0.57 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | BMP4 | P12644 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446361 | 0.74 | SMPD3 (0.38) | SMPD3NUDT1AXLCDK2BMP4 | |
| SCHEMBL3122125 | 0.74 | SMPD3 (0.38) | SMPD3NUDT1AXLCDK2BMP4 | |
| SCHEMBL4569294 | 0.74 | SMPD3 (0.38) | SMPD3NUDT1AXLCDK2BMP4 | |
| SCHEMBL9935120 | 0.74 | SMPD3 (0.38) | SMPD3NUDT1AXLCDK2BMP4 | |
| SCHEMBL9124027 | 0.74 | SMPD3 (0.39) | SMPD3AXLCDK2BMP4POLB | |
| SCHEMBL3023258 | 0.74 | SMPD3 (0.40) | SMPD3NUDT1AXLBMP4PIM1 | |
| SCHEMBL5791049 | 0.72 | SMPD3 (1.00) | SMPD3AXLCDK2BMP4IRAK4 | |
| SCHEMBL398829 | 0.72 | MAP4K4 (0.60) | SMPD3AXLMAP4K4 | |
| Hydrochloric Acid SCHEMBL3702394 | 0.72 | SMPD3 (0.37) | SMPD3NUDT1AXLCDK2BMP4 | |
| Hydrochloric Acid SCHEMBL31619326 | 0.72 | SMPD3 (0.38) | SMPD3AXLCDK2BMP4POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028131-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2023-11-22 | — | — | EP | claimed |
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-11 | — | — | US | disclosed |
| CN-113423708-B | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2025-04-22 | — | — | CN | disclosed |
| EP-4522607-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-kB INDUCING KINASE | JANSSEN Pharmaceutica NV (BE) | 2025-03-19 | — | — | EP | disclosed |
| CN-113454086-B | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119317626-A | Pyrrolidone derivatives as inhibitors of NF- κb-induced kinase | 詹森药业有限公司 | 2025-01-14 | — | — | CN | disclosed |
| WO-2023217851-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF-κB INDUCING KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-16 | — | — | WO | disclosed |
| EP-4055026-A1 | COMPOUNDS AS CD73 INHIBITORS | Bioardis LLC (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022061155-A1 | IMIDAZOPYRIDAZINE AND IMIDAZOPYRAZINE COMPOUNDS AS INHIBITORS OF CDK7 | THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC (US) | 2019-05-09 | — | — | US | disclosed |
| US-10280184-B2 | Heterocyclic kinase inhibitors | ABBVIE INC. (US) | 2019-05-07 | — | — | US | disclosed |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | EFFECTOR THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBVIE INC. | 2017-04-27 | — | — | US | disclosed |
| EP-1928879-B1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2013-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282768-A1 | PYRROLIDINONE DERIVATIVES AS INHIBITORS OF NF KAPPA B INDUCING KINASE | NFKBIA, IKBKG, IKBKB | SMPD3 2082/4885NUDT1 2530/4885AXL 4714/4885 |
| US-10280184-B2 | Heterocyclic kinase inhibitors | MAP3K1, MAP3K20, MAP3K19 | SMPD3 2027/4885NUDT1 1271/4885AXL 419/4885 |
| US-20170114077-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | SMPD3 2027/4885NUDT1 1271/4885AXL 419/4885 |
| US-20190135836-A1 | HETEROCYCLIC KINASE INHIBITORS | MAP3K1, MAP3K20, MAP3K19 | SMPD3 2015/4885NUDT1 1385/4885AXL 407/4885 |
| US-20170145009-A1 | HETEROCYCLIC COMPOUNDS THAT INHIBIT THE KINASE ACTIVITY OF MNK USEFUL FOR TREATING VARIOUS CANCERS | MAP3K9, MAP3K19, MAP3K20 | SMPD3 3576/4885NUDT1 2911/4885AXL 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.